A blood sample could one day be enough to diagnose many types of solid cancers, or to monitor the amount of cancer in a patient’s body and responses to treatment.
Previous versions of the approach, which relies on monitoring levels of tumor DNA circulating in the blood, have required cumbersome and time-consuming steps to customize it to each patient or have not been sufficiently sensitive.
Now, researchers at the Stanford University School of Medicine have devised a way to quickly bring the technique to the clinic. Their approach, which should be broadly applicable to many types of cancers, is highly sensitive and specific. With it they were able to accurately identify about 50 percent of people in the study with stage-1 lung cancer and all patients whose cancers were more advanced.
“We set out to develop a method that overcomes two major hurdles in the circulating tumor DNA field,” said Maximilian Diehn, MD, PhD, the CRK Faculty Scholar and assistant professor of radiation oncology. “First, the technique needs to be very sensitive to detect the very small amounts of tumor DNA present in the blood. Second, to be clinically useful it’s necessary to have a test that works off the shelf for the majority of patients with a given cancer.”
The researchers describe their findings in a paper published online April 6 in Nature Medicine. Diehn shares senior authorship with Ash Alizadeh, MD, PhD, assistant professor of medicine. Postdoctoral scholars Aaron Newman, PhD, and Scott Bratman, MD, PhD share lead authorship.
“We’re trying to develop a general method to detect and measure disease burden,” said Alizadeh, a hematologist and oncologist. “Blood cancers like leukemias can be easier to monitor than solid tumors through ease of access to the blood. By developing a general method for monitoring circulating tumor DNA, we’re in effect trying to transform solid tumors into liquid tumors that can be detected and tracked more easily.”
Even in the absence of treatment, cancer cells are continuously dividing and dying. As they die, they release DNA into the bloodstream, like tiny genetic messages in a bottle. Learning to read these messages — and to pick out the one in 1,000 or 10,000 that come from a cancer cell — can allow clinicians to quickly and noninvasively monitor the volume of tumor, a patient’s response to therapy and even how the tumor mutations evolve over time in the face of treatment or other selective pressures.
“The vast majority of circulating DNA is from normal, non-cancerous cells, even in patients with advanced cancer,” Bratman said. “We needed a comprehensive strategy for isolating the circulating DNA from blood and detecting the rare, cancer-associated mutations. To boost the sensitivity of the technique, we optimized methods for extracting, processing and analyzing the DNA.
The researchers’ technique, which they have dubbed CAPP-Seq, for Cancer Personalized Profiling by deep Sequencing, is sensitive enough to detect just one molecule of tumor DNA in a sea of 10,000 healthy DNA molecules in the blood. Although the researchers focused on patients with non-small-cell lung cancer (which includes most lung cancers, including adenocarcinomas, squamous cell carcinoma and large cell carcinoma), the approach should be widely applicable to many different solid tumors throughout the body. It’s also possible that it could one day be used not just to track the progress of a previously diagnosed patient, but also to screen healthy or at-risk populations for signs of trouble.
Tumor DNA differs from normal DNA by virtue of mutations in the nucleotide sequence. Some of the mutations are thought to be cancer drivers, responsible for initiating the uncontrolled cell growth that is the hallmark of the disease. Others accumulate randomly during repeated cell division. These secondary mutations can sometimes confer resistance to therapy; even a few tumor cells with these types of mutations can expand rapidly in the face of seemingly successful treatment.
Different from patient to patient
“Cancer is a genetic disease,” Alizadeh said. “But unlike Down syndrome, for example, which has a single dominant cause, for most cancers it’s very difficult to identify any one particular genetic aberration or mutation that is found in every patient. Instead, each cancer tends to be genetically different from patient to patient, although sets of mutations can be shared among patients with a given cancer.”
The Latest on: Cancer blood test
via Google News
The Latest on: Cancer blood test
- World Cancer Day: SA men urged to spearhead cancer awarenesson February 4, 2020 at 6:10 am
Black men had the highest chance of contracting prostate cancer, with a high-risk rate of up to one in four or 25 percent, while the risk for white men was at 10 percent, Strauss said. "Any man over ...
- Cancer deaths decline in US, with advances in prevention, detection and treatmenton February 4, 2020 at 5:31 am
Targeted inhibitors have also revolutionized the treatment and prognosis of chronic lymphocytic leukemia and a number of other blood cancers ... much less cutting-edge, cancer care remains limited, ...
- 2020 Italy Cancer Diagnostics Market - Abbott, Becton Dickinson, Exact Sciences, OncoLab & Wako Pure Chemicals - ResearchAndMarkets.comon February 4, 2020 at 4:17 am
Business Opportunities and Strategic Recommendations Cancer Diagnostic Tests & Over 200 current and emerging assays including ... Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, ...
- Cervical Cancer Treatment Market Size, Top Vendors, Industry Challenges and Forecasts to 2026on February 4, 2020 at 3:29 am
Cervical Cancer Treatment Market The Cervical Cancer Treatment market report offers a detailed assessment of the global Cervical Cancer Treatment market by using quantitative and qualitative insights, ...
- Colorectal Cancer Screening Market Analysis by Experts 2020 to 2024on February 3, 2020 at 9:59 pm
Colorectal Cancer Screening Market – Growth, Trends And Forecast (2020 – 2024) Colorectal cancer (CRC) is known as bowel cancer and colon cancer. It is the development of cancer from the colon or ...
- Cross Party Group acknowledges need for early lung cancer screening in Scotlandon February 3, 2020 at 6:40 pm
“Many more lives could be saved if lung cancer was diagnosed earlier through a screening program” said Dr Adam M Hill, Chief Executive of Oncimmune who was a guest speaker at the Cross Party Group ...
- 3 startups developing blood tests to help detect cancer earlieron February 3, 2020 at 8:12 am
Three startups with funding from major technologies companies are working to receive FDA approval on blood tests that screen for cancer, according to CNBC. Freenome, a startup with backing from ...
- Researchers reveal mutation's role in blood cancerson February 3, 2020 at 4:30 am
I'm a hematological oncologist--I think a lot about blood cancer--so this caught my attention right away ... ASO therapy has been effective in combating other diseases resulting from defective RNA ...
- These Start-Ups Are Racing to Help Doctors Detect Cancer Early With a Simple Blood Teston February 1, 2020 at 3:47 pm
Getting a blood test to screen for cancer in the earliest stages might seem like a pipe dream. But a group of biotech entrepreneurs say they’re close to making it a reality. If Gabriel Otte’s start-up ...
- University of Pennsylvania researchers nab grant for CAR-T prostate cancer teston January 31, 2020 at 6:57 am
The University of Pennsylvania, which has helped pioneer cell therapy approaches to blood cancers, has nabbed an ACGT grant to help battle solid tumors. The research team has been handed a $500,000 ...
via Bing News